Price movement over the last 24 hours
Abbott Laboratories vs Hershey Co — how do they compare? Abbott Laboratories trades at $95.33 (market cap $166.94B), while Hershey Co trades at $175.05 (market cap $35.69B). The key difference: Abbott Laboratories is far larger — about 4.7× Hershey Co's market cap, and Hershey Co pays the higher dividend (3.3%). Which is the better fit depends on your goals.
| ABT | HSY | |
|---|---|---|
Market Cap | $166.94B | $35.69B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $236.28 |
52-Week Low | $82.57 | $161.95 |
Enterprise Value | $193.69B | $40.49B |
Dividend Yield | 2.63% | 3.3% |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Hershey (HSY) trades at $175.95, down 3.4% over the past day, with a bearish technical signal but strong recent earnings beats. The stock shows a high P/E ratio of 33.06 and a net income margin of 9.12%, supported by consistent cash flow from operations of $2.28B in 2025. Recent corporate actions include a $1.45 dividend and executive appointments, while cocoa cost pressures show signs of easing according to MarketBeat (July 1, 2026).
The outlook is mixed: analyst consensus targets $211.27 with 65.72% hold ratings, indicating cautious optimism amid valuation concerns. Key risks include commodity inflation and competitive pressures, but margin recovery and dividend yield near 3.2% offer potential for income-focused investors. Upside depends on sustained earnings growth and cost management.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →